Treatment of Murine Fusariosis with SCH 56592

AUTOR(ES)

Lozano-Chiu, M.

FONTE

American Society for Microbiology

RESUMO

Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused by F. solani.

Documentos Relacionados

• Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis.
• Treatment of murine coccidioidal meningitis with SCH39304.
• Efficacy of Liposomal Amphotericin B in Treatment of Systemic Murine Fusariosis
• Treatment of murine cryptococcal meningitis with an SCH 39304-amphotericin B combination.
• Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia